NCT04192500View on ClinicalTrials.gov

Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

September 7, 2020

Study Completion Date

September 7, 2020

Conditions
Influenza
Interventions
BIOLOGICAL

OVX836

One single administration intramuscularly at Day 1.

BIOLOGICAL

Quadrivalent seasonal influenza vaccine (Influvac TetraTM)

One single administration intramuscularly at Day 1.

Trial Locations (1)

9000

Centre for Vaccinology (CEVAC), Ghent

Sponsors

Lead Sponsor

Osivax
All Listed Sponsors
collaborator

Centre for vaccinology (CEVAC), University of Ghent

UNKNOWN

lead

Osivax

INDUSTRY